Carr, Michael J.
Sun, James
DePalo, Danielle
Rothermel, Luke D.
Song, Yun
Straker, Richard J.
Baecher, Kristin
Louie, Raphael J.
Stahlie, Emma H. A.
Wright, G. Paul
Naqvi, Syeda Mahrukh Hussnain
Kim, Youngchul
Sarnaik, Amod A.
Karakousis, Giorgos C.
Lowe, Michael C.
Delman, Keith A.
van Akkooi, Alexander C. J.
Ollila, David W.
Collichio, Frances
Zager, Jonathan S.
Article History
Received: 11 August 2020
Accepted: 31 August 2021
First Online: 14 October 2021
Disclosure
: J.S. has received research funding from Amgen. A.v.A. receives advisory board and consultancy honoraria from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Sanofi and 4SC, all paid to the institution. He has received research grants from Amgen, Bristol-Myers Squibb, and Novartis, all paid to the institution. F.C.’s institution receives research funding from Amgen, Merck and Novartis, a portion of which supports her salary. J.S.Z. has advisory board relationships with Merck speaker’s bureau for Pfizer and Sun Pharma. He also receives research funding from Amgen, Delcath Systems, Philogen, Provectus and Novartis. He also is a member of the speaker’s bureau for Amgen and SunPharma. A.S.—Consulting fees and sponsored travel from Iovance Biotherapeutics Inc. Consulting fees from Guidepoint and Defined Health Inc. Honorarium and sponsored travel from Physicians' Educational Resource, LLC. Patent royalties from methods to improve adoptive cell therapy using tumor-infiltrating lymphocytes. None of the financial disclosures are related to this present work. The remaining authors have no relevant conflicts of interest to disclose.